在牛皮中IL-23抑制剂:我们到目前为止学到了什么?
Matteo Megna1, Michela D'Agostino1, Federica Feo1
1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Journal of inflammation research
|February 19, 2026
概括
干白素-23 (IL-23) 抑制剂为中度至重度的斑块性牛皮提供有效的,持久的治疗方法. 现实世界的数据证实了它们在不同患者群体和具有挑战性的疾病部位的安全性和有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- IL-23/Th17轴是中度至重度斑块性牛皮病原体的核心.
- 针对p19亚单元的IL-23抑制剂提供了一种有针对性的方法来抑制炎症.
- 随机试验显示高效率和安全性,但复杂人群需要真实世界的数据.
研究的目的:
- 审查IL-23抑制剂在牛皮的长期疗效,耐用性和安全性的现实证据.
- 评估IL-23抑制剂在特殊和并发症患者群体中的性能.
- 综合试验和现实世界的数据,用于对IL-23抑制剂使用的临床指导.
主要方法:
- 扩大真实世界的证据的叙事审查.
- 从关键随机试验和大型观察队列中整合数据.
- 关注不同患者群体的长期结果,药物存活率和安全性.
主要成果:
- 现实世界的研究证实了高效率在老年,并发病和重量预先治疗的患者.
- IL-23抑制剂在患有特定并发症的患者中表现出优异的治疗持久性和良好的安全性.
- 观察到难以治疗的区域,如头皮,指甲和棕植物区域的持续有效性.
结论:
- IL-23抑制剂是多功能,可靠的长期治疗牛皮,解决临床实践中未满足的需求.
- 现实世界的数据支持跨异质患者群体的持续有效性和安全性.
- 药物之间存在微妙的差异,guselkumab和risankizumab表现出更快的早期反应,而tildrakizumab提供剂量灵活性.
相关概念视频
T Cell Types and Functions
2.7K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
531
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
531
iPS Cell Differentiation
3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
607
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
607
The JAK-STAT Signaling Pathway
13.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
574
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
574


